EMA's CHMP Recommends Oral Wegovy Approval, Expanding Obesity Treatment Options in Europe
Decision brief
Answer first · skim in under a minute
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of an oral formulation of Wegovy for weight management. This recommendation signifies a crucial step towards increased accessibility of GLP-1 receptor agonist therapies for obesity in Europe.
On 21 May 2026, the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for oral Wegovy (semaglutide) tablets—the first oral GLP-1 receptor agonist recommended for weight management in the EU. The opinion still needs a European Commission decision before patients can access the pill under EU marketing authorisation.
Contents9 sections
Key Takeaways
- CHMP positive opinion on 21 May 2026 adds Wegovy tablets (1.5 mg, 4 mg, 9 mg, 25 mg) as a new oral form and route.
- EMA describes the tablets as the first oral GLP-1 treatment for weight management recommended in the EU.
- Proposed use mirrors injectable Wegovy’s adult BMI thresholds with diet and activity; prescription-only, once daily with fasting rules.
- Commission authorisation and national reimbursement remain outstanding; injectable Wegovy indications are unchanged.
What did the EMA CHMP decide on oral Wegovy?
The CHMP recommended a change to Novo Nordisk A/S’s marketing authorisation for Wegovy to add tablets for oral use. The EMA variation page lists four new strengths: 1.5 mg, 4 mg, 9 mg and 25 mg.
A parallel EMA news release dated 22 May 2026 frames the opinion as the first oral GLP-1 for weight management in the EU and notes that tablets are taken once daily on an empty stomach after at least eight hours of fasting, with a 30-minute wait before eating, drinking or other medicines.
Who is the oral formulation intended for?
Under the CHMP summary of opinion, Wegovy tablets are indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with:
- BMI ≥30 kg/m² (obesity), or
- BMI ≥27 to <30 kg/m² (overweight) plus at least one weight-related comorbidity (for example dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease).
The CHMP summary of opinion PDF states that injectable Wegovy indications remain unchanged pending the Commission decision.
How does this change Novo Nordisk’s EU obesity franchise?
Injectable Wegovy already holds EU authorisation. Adding a daily tablet creates a two-format semaglutide weight-management portfolio for the same adult BMI bands. That matters for patients who prefer oral dosing and for payers comparing adherence, cold-chain logistics and list-price negotiations against weekly injectables.
Competitive pressure in EU obesity care already includes other GLP-1 and dual agonists. An oral option does not automatically win formulary share; Member States still set price and reimbursement after Commission authorisation.
For commercial teams, the practical questions are supply of the four tablet strengths, co-pay support where allowed, and whether oral dosing expands treated prevalence or mainly switches existing injectable users. EMA’s note that patients must fast eight hours and wait 30 minutes before other medicines will shape counseling scripts in primary care and endocrinology clinics.
Investors should also separate CHMP opinion news from U.S. oral semaglutide dynamics. EU authorisation timing, national HTA calendars and manufacturing capacity each move on different clocks. Related context on supply and demand appears in our coverage of Wegovy manufacturing capacity.
What happens after a CHMP positive opinion?
EMA’s news note is explicit: the opinion is an intermediary step. The European Commission adopts the decision on the extension. Only then do Member States decide price and reimbursement in their health systems. The CHMP summary notes that Commission decisions normally issue about 67 days after the opinion.
Until that decision publishes, oral Wegovy is not an authorised EU presentation. Claims about launch timing in specific countries should wait for Commission text and local HTA outcomes.
What remains unproven for oral Wegovy in Europe?
The CHMP opinion does not itself set reimbursement rates, supply commitments or real-world adherence versus weekly injections. Full SmPC updates appear only after Commission authorisation. Cardio-metabolic label nuances beyond the BMI indication language should be checked in the final SmPC, not assumed from injectable SELECT narratives alone.
Related NovaPharma coverage
- EMA Approves Novo's Wegovy: A Game Changer in Weight Loss
- Novo Nordisk Wegovy Data for Women with Obesity at ECO 2026
- FDA Approves Higher-Dose Wegovy 7.2mg for Weight Loss
Frequently Asked Questions
What did the EMA CHMP decide on oral Wegovy?
On 21 May 2026, the CHMP adopted a positive opinion recommending a variation to add Wegovy tablets for oral use in four strengths (1.5 mg, 4 mg, 9 mg and 25 mg) for adult weight management.
Who can receive oral Wegovy under the CHMP-recommended indication?
Adults with BMI ≥30 kg/m², or BMI ≥27 to <30 kg/m² with at least one weight-related comorbidity such as dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease, as an adjunct to diet and physical activity.
Is oral Wegovy already authorised across the EU?
Not yet. A CHMP positive opinion is an intermediary step; the European Commission still must adopt a decision on the marketing authorisation extension before Member State pricing and reimbursement decisions.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Wegovy.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
